A case of multisystem Langerhans cell histiocytosis presenting as central diabetes insipidus
Open Access
- 2 November 2019
- journal article
- case report
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 9 (6) , 515-517
Abstract
Langerhans cell histiocytosis (LCH) is a rare malignancy most commonly characterized by histiocytic infiltration of bone. LCH lesions in the skull place the adjacent central nervous system (CNS) at risk for involvement, which can manifest as central diabetes insipidus (CDI) when there is infiltration of the hypothalamic-pituitary axis. We present a case of a 39-year-old female who presented with polyuria and polydipsia for 1 year and left-sided hearing loss, gait instability, and nystagmus for 5 days. She was found on laboratory evaluation to have CDI and underwent left cortical mastoidectomy for a destructive peripherally enhancing mastoid lesion seen on MRI brain. Pathology revealed CD1a and S100+ LCH and the patient was subsequently discharged to begin outpatient chemotherapy with vinblastine and prednisone. The patient’s CDI was diagnostic of CNS involvement, making her LCH multisystem through the infiltration of both the skull and hypothalamic-pituitary structures. As CDI can be seen in up to 25% of single-system LDH, and up to 50% of multisystem cases, radiologic studies to evaluate for osteolytic skull lesions must be considered as part of the evaluation for LCH when CDI has been diagnosed.Keywords
This publication has 11 references indexed in Scilit:
- Central diabetes insipidus: beware of Langerhans cell histiocytosis!2018
- Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective studyOrphanet Journal of Rare Diseases, 2017
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesBlood, 2016
- BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groupsJournal of Experimental Medicine, 2014
- Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosisBlood, 2013
- Central Nervous System Disease in Langerhans Cell HistiocytosisThe Journal of Pediatrics, 2010
- Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans CellsThe Journal of Immunology, 2010
- Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensificationBlood, 2008
- Adult Langerhans cell histiocytosisEuropean Journal of Haematology, 2006
- A randomized trial of treatment for multisystem Langerhans’ cell histiocytosisThe Journal of Pediatrics, 2001